TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36424664

Group type: EXPERIMENTAL
Intervention: 3.000-m run in the morning (7:00-8:00 a.m.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3.000-m run in the evening (7:00-8:00 p.m.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Incremental treadmill test in the morning (7:00-8:00 a.m.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Incremental treadmill test in the evening (7:00-8:00 p.m.)
Number of subjects: 15
Study: 34945234

Group type: EXPERIMENTAL
Intervention: Remote hospital care including oxygen therapy, medication, and remote monitoring.
Number of subjects: 62

Group type: COMPARATOR
Intervention: In-hospital care as usual (control group).
Number of subjects: 62
Study: 35662283

Group type: EXPERIMENTAL
Intervention: Nivolumab (nivo) with chemotherapy (gemcitabine/nab-paclitaxel)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sotigalimab (sotiga) with chemotherapy (gemcitabine/nab-paclitaxel)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sotigalimab (sotiga) with nivolumab (nivo) and chemotherapy (gemcitabine/nab-paclitaxel)
Number of subjects: 105
Study: 33761458

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aerobic Training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 45
Study: 32179792

Group type: EXPERIMENTAL
Intervention: Intraoperative ATP (8 impulses à 6 Volt x 1.0 milliseconds)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Without intraoperative ATP
Number of subjects: 150

Group type: COMPARATOR
Intervention: Without ATP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: With ATP
Number of subjects: 150
Study: 36342113

Group type: EXPERIMENTAL
Intervention: Pemafibrate (0.2-mg tablets twice daily)
Number of subjects: 10497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10497

Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 10497

Group type: COMPARATOR
Intervention: Pemafibrate vs Placebo
Number of subjects: 10497
Study: 33277288

Group type: EXPERIMENTAL
Intervention: Continuous skin-to-skin contact
Number of subjects: 11

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 11
Study: 33323188

Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support for 3 months, offers of referral to external smoking cessation services, and brief advice.
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Brief advice alone (control group).
Number of subjects: 1185
Study: 34501540

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program (interactive oral activities, tongue strength training, oral cleaning procedure)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Phase 1 (usual activities, baseline data collection)
Number of subjects: 41
Study: 32601641

Group type: EXPERIMENTAL
Intervention: Methicillin‐Resistant Staphylococcus aureus (MRSA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Infected burn injuries
Number of subjects: 250
Study: 33615398

Group type: EXPERIMENTAL
Intervention: CBT combined with medication (CBT + M)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Medication only (M)
Number of subjects: 98
Study: 33291973

Group type: EXPERIMENTAL
Intervention: Basic implementation strategy via an internal coordinator
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Depression services implementation via an internal coordinator and an external quality assurance committee
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both intervention packages
Number of subjects: 10
Study: 32846334

Group type: EXPERIMENTAL
Intervention: High-altitude pulmonary rehabilitation (HAPR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sea-level pulmonary rehabilitation (LAPR)
Number of subjects: 138
Study: 34813962

Group type: EXPERIMENTAL
Intervention: Telemedicine access to specialty medical care
Number of subjects: 624

Group type: COMPARATOR
Intervention: Usual care (offsite specialty referral)
Number of subjects: 624
Study: 32881148

Group type: EXPERIMENTAL
Intervention: Desire thinking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral thinking
Number of subjects: 60
Study: 35266842

Group type: EXPERIMENTAL
Intervention: Posttraumatic Growth Inventory (PTGI)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Stress-Related Growth Scale (SRGS)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Guided-steps version of the SRGS
Number of subjects: 616

Group type: COMPARATOR
Intervention: Original SRGS
Number of subjects: 616
Study: 34347808

Group type: EXPERIMENTAL
Intervention: Oral phloroglucinol (Flospan®)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 32600320

Group type: EXPERIMENTAL
Intervention: Lactose challenge (50 g lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional milk (750 mL, 37.5 g lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: A1 β-casein-free milk (a2 Milk™) (750 mL, 37.5 g lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Existing literature cut-off values for breath H2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Breath H2 optimal cut-off value
Number of subjects: 40
Study: 36195894

Group type: EXPERIMENTAL
Intervention: Digital fetal scalp stimulation (dFSS)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Fetal blood sampling (FBS)
Number of subjects: 2500
Study: 34445008

Group type: EXPERIMENTAL
Intervention: Aerobic exercise + weight loss (AEX + WL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Weight loss (WL)
Number of subjects: 100
Study: 33422174

Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy 20 mg once a week
Number of subjects: 1

Group type: COMPARATOR
Intervention: Hydroxychloroquine 400 mg daily with topical minoxidil
Number of subjects: 1
Study: 35843459

Group type: EXPERIMENTAL
Intervention: Vitamin D (60,000 IU every 5 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33866774

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor (gemigliptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPP-4 inhibitor (sitagliptin)
Number of subjects: 0
Study: 34410358

Group type: EXPERIMENTAL
Intervention: Cipargamin (KAE609) single doses of 50 to 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cipargamin (KAE609)
Number of subjects: 0
Study: 33522951

Group type: EXPERIMENTAL
Intervention: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30%, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32515740

Group type: EXPERIMENTAL
Intervention: Coach-guided web-based therapy (The Journal) for 12 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Information-only waitlist control (leaflet of mental health resources)
Number of subjects: 95
Study: 34130573

Group type: EXPERIMENTAL
Intervention: Proactive management with Cal/BD foam (twice-weekly application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive management with Cal/BD foam (once-daily for four weeks after relapse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive management with Cal/BD foam
Number of subjects: 0
Study: 33548084

Group type: EXPERIMENTAL
Intervention: Quadruple single-pill combination (reserpine 0.1 mg, dihydralazine 12.5 mg, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quadruple single-pill combination
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatment and placebo groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 35969408

Group type: EXPERIMENTAL
Intervention: Enhanced self-measured blood pressure (SMBP) using a device paired with a connected smartphone application.
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Standard self-measured blood pressure (SMBP) device.
Number of subjects: 2101

Group type: EXPERIMENTAL
Intervention: Enhanced SMBP
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Standard SMBP
Number of subjects: 2101
Study: 33186774

Group type: EXPERIMENTAL
Intervention: 10 % povidone‐iodine vaginal disinfection for 30 s
Number of subjects: 270

Group type: COMPARATOR
Intervention: No vaginal disinfection (control)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 10 % povidone‐iodine vaginal disinfection
Number of subjects: 270
Study: 36727153

Group type: EXPERIMENTAL
Intervention: Aspirin plus prasugrel
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 76
Study: 34677005

Group type: EXPERIMENTAL
Intervention: Hypochlorite-based formula brushing solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorhexidine toothpaste and mouthwash
Number of subjects: 40
Study: 32969733

Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (saline 0.9% NaCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg/kg and 2 mg/kg
Number of subjects: 8
Study: 36350593

Group type: EXPERIMENTAL
Intervention: uRDN
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 136
Study: 33516795

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (NPWT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 124
Study: 33728040

Group type: EXPERIMENTAL
Intervention: Pen included with questionnaire
Number of subjects: 1466

Group type: COMPARATOR
Intervention: No pen included with questionnaire
Number of subjects: 1466
Study: 35654369

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Constant-Load Exercise (CLE)
Number of subjects: 55
Study: 33547927

Group type: EXPERIMENTAL
Intervention: App-based exercise program (GenuSport)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular physiotherapy (control group)
Number of subjects: 35
Study: 32815438

Group type: EXPERIMENTAL
Intervention: Figure-of-eight suture technique (ES group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Manual compression (MC group)
Number of subjects: 152
Study: 35299213

Group type: EXPERIMENTAL
Intervention: Musical intervention (listening to Music Care application via headphones)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (no music)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Musical intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 72
Study: 33427754

Group type: EXPERIMENTAL
Intervention: Continuous warming of human milk (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hot water bath warming of human milk (n = 22)
Number of subjects: 44
Study: 34643944

Group type: EXPERIMENTAL
Intervention: Machine-learning model (XGBoost) for screening cognitive impairment
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Hypothetical ED model for screening
Number of subjects: 1736
Study: 32358216

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person clinic visits
Number of subjects: 0
Study: 34741103

Group type: EXPERIMENTAL
Intervention: Rotarix (live‐attenuated, oral rotavirus vaccine)
Number of subjects: 180
Study: 32609331

Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl (IPE) 4 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33054728

Group type: EXPERIMENTAL
Intervention: Fear of falling (FoF) assessed using the Short Falls Efficacy Scale International
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Subjective functional capacity
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Fear of falling (FoF)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: EQ-5D descriptive system and EQ-VAS
Number of subjects: 309
Study: 35064942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ethanol (approximately 0.7 ml/kg)
Number of subjects: 108
Study: 34620496

Group type: EXPERIMENTAL
Intervention: Ceralasertib 160 mg orally daily (days 1-7) and olaparib 300 mg orally twice daily (days 1-28) of a 28-day cycle until toxicity or progression
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ceralasertib plus olaparib
Number of subjects: 14
Study: 35462033

Group type: EXPERIMENTAL
Intervention: Guideline-Directed Medical Therapy (GDMT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzymes/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 150
Study: 33501978

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 284

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 284
Study: 35048423

Group type: EXPERIMENTAL
Intervention: AZ-009 (2 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AZ-009 (3 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AZ-009 (4 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 33268527

Group type: COMPARATOR
Intervention: Active conventional treatment (either prednisolone tapered to 5 mg/day, or sulfasalazine combined with hydroxychloroquine and intra‐articular corticosteroids)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 812
Study: 35819787

Group type: EXPERIMENTAL
Intervention: Family-Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 252
Study: 33024022

Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon Beta-1a (IFN‐β‐1a)
Number of subjects: 0
Study: 34800699

Group type: EXPERIMENTAL
Intervention: 4 Youth by Youth (4YBY) implementation strategy
Number of subjects: 0
Study: 33771941

Group type: EXPERIMENTAL
Intervention: 8/4 self-paced interval training session
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 4/2 self-paced interval training session
Number of subjects: 11
Study: 32176006

Group type: EXPERIMENTAL
Intervention: Infraorbital region taping (TG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nontaping group (Control)
Number of subjects: 64
Study: 35810757

Group type: EXPERIMENTAL
Intervention: Direct endovascular thrombectomy
Number of subjects: 295

Group type: COMPARATOR
Intervention: Bridging therapy (intravenous thrombolytic before endovascular thrombectomy)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 295
Study: 33780749

Group type: EXPERIMENTAL
Intervention: Educational-motivational intervention (physician-led integrated intervention with educational session and motivational interviewing phone sessions)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 360
Study: 34155159

Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine (DEX) administered at an initial dose of 1 µg/kg over 10 minutes, followed by a continuous infusion at 0.4 μg/kg/h until 30 minutes before the end of surgery.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral superficial cervical plexus block (SCPB) with 10 mL of 0.375% ropivacaine injected on each side.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous saline administered at the same rate and dose as in group D.
Number of subjects: 90
Study: 616684303

Group type: EXPERIMENTAL
Intervention: Sheathless common 7-F guiding catheter
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional 6-F sheath guiding catheter
Number of subjects: 160
Study: 35139044

Group type: EXPERIMENTAL
Intervention: Intrathecal chloroprocaine 49.5 mg with fentanyl 10 ug
Number of subjects: 45
Study: 33027448

Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational programme on cardiovascular prevention for children; exposure for one year
Number of subjects: 418

Group type: COMPARATOR
Intervention: Written cardiovascular health educational brochures for parents (Control)
Number of subjects: 418
Study: 36188435

Group type: EXPERIMENTAL
Intervention: RQ3013 (30 μg mRNA per 0.15 mL)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: ChAdTS-S (5×10^10 viral particles per 0.5 mL)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: ZR202-CoV (25 μg per 0.5 mL)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: CoronaVac (3 μg inactivated CN02 strain of SARS-CoV-2 per 0.5 mL)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo (0.5 mL of 0.9% sodium chloride solution)
Number of subjects: 235
Study: 33452059

Group type: EXPERIMENTAL
Intervention: Diabetes-focused CBT delivered by diabetes specialist nurses (10 sessions over 12 months)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diabetes-focused CBT
Number of subjects: 71
Study: 33212268

Group type: EXPERIMENTAL
Intervention: Violet LED
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 7.5 % hydrogen peroxide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 7.5 % hydrogen peroxide + violet LED
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 22 % carbamide peroxide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 22 % carbamide peroxide + violet LED
Number of subjects: 90

Group type: COMPARATOR
Intervention: No bleaching (control)
Number of subjects: 90
Study: 33078466

Group type: EXPERIMENTAL
Intervention: Uncomplicated monochorionic twin pregnancies
Number of subjects: 3873

Group type: COMPARATOR
Intervention: Dichorionic twin pregnancies
Number of subjects: 3873
Study: 35182121

Group type: EXPERIMENTAL
Intervention: Cervical perforated pessary (CPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pessary)
Number of subjects: 0
Study: 33461539

Group type: EXPERIMENTAL
Intervention: Motor imagery associated with actual practice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Real practice only (Control)
Number of subjects: 40
Study: 32737344

Group type: EXPERIMENTAL
Intervention: More years of schooling
Number of subjects: 0
Study: 35630045

Group type: EXPERIMENTAL
Intervention: Group A (warm-up, aerobic training, strength training, stretching, cool down)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group B (warm-up, strength training, aerobic training, stretching, cool down)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control Group C (no exercise)
Number of subjects: 91
Study: 32975556

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 32466678

Group type: EXPERIMENTAL
Intervention: Pap�s Saludables Ni�os Saludables intervention
Number of subjects: 36
Study: 33580340

Group type: COMPARATOR
Intervention: α‐tocopherol 0 IU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: α‐tocopherol 40 IU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: α‐tocopherol 70 IU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: α‐tocopherol 90 IU
Number of subjects: 20
Study: 35633654

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inulin+Traditional Chinese Medicine (TCM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inulin+Metformin
Number of subjects: 60
Study: 33918630

Group type: EXPERIMENTAL
Intervention: Micronutrient intervention (not specified in detail)
Number of subjects: 100
Study: 32789480

Group type: EXPERIMENTAL
Intervention: PCb (paclitaxel 80 mg/m2 and carboplatin [AUC = 2] on days 1, 8, and 15 every 28 days for 6 cycles)
Number of subjects: 647

Group type: COMPARATOR
Intervention: CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: PCb
Number of subjects: 647
Study: 35762659

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 803
Study: 35869929

Group type: EXPERIMENTAL
Intervention: HDIT101 (doses up to 12,150 mg)
Number of subjects: 24
Study: 36162740

Group type: EXPERIMENTAL
Intervention: MPT IVR
Number of subjects: 25
Study: 33503610

Group type: EXPERIMENTAL
Intervention: One Strength Group (3 injections with 1 strength B, 10,000 TU/mL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard group (7 injections with 2 strengths A (1,000 TU/mL) and B (10,000 TU/mL))
Number of subjects: 87
Study: 32833762

Group type: EXPERIMENTAL
Intervention: Stenting as bridge‐to‐surgery (SBTS)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Stenting as bridge‐to‐surgery (SBTS) (descending colon obstruction)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Emergency surgery (ES)
Number of subjects: 115
Study: 33070326

Group type: EXPERIMENTAL
Intervention: Water as a neutralising agent
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sodium bicarbonate plus solution (Control)
Number of subjects: 126
Study: 34128822

Group type: EXPERIMENTAL
Intervention: MyBackPain website access
Number of subjects: 453

Group type: COMPARATOR
Intervention: Unguided internet use
Number of subjects: 453
Study: 35024596

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 34548195

Group type: EXPERIMENTAL
Intervention: Tissue engineered construct (collagen/osteogenically differentiated bone marrow‐derived mesenchymal stem cells)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Autogenous anterior iliac crest (AIC) bone graft
Number of subjects: 10
Study: 34515079

Group type: EXPERIMENTAL
Intervention: Osteopathic medicine (OM) sessions (up to six sessions) in addition to routine care
Number of subjects: 40